- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Avalere's Ryan Urgo on the Biden Administration's Options to Tackle Drug Pricing
Avalere is presenting at Asembia’s 2022 Specialty Pharmacy Summit, and Ryan Urgo, MPAP, managing director, health policy, discusses possible drug pricing policy options on the table for the Biden administration to consider in a midterm election year.
Avalere is presenting at Asembia’s 2022 Specialty Pharmacy Summit, and Ryan Urgo, MPAP, managing director, health policy, is one of the panel members who will discuss possible drug pricing policy options and other health care issues for the Biden administration to consider, in a talk called “Evolution of Biden’s Healthcare Agenda in an Election Year.”
Transcript
Every administration wants to tackle high drug prices. What is Biden’s plan to move forward from Build Back Better and introduce and implement policies that do address prescription drug prices?
I think that the first order of business for the administration is to see if the legislative process bears fruit before the midterm elections. And they would try to get something done on Medicare negotiation, inflation, rebate penalties, and potentially Medicare Part D redesign. If that effort fails, it would be a safe bet to expect the administration pivots towards using their regulatory authority to try to get some of these similar policies through, but that would be through the confines of a demonstration through CMMI [Center for Medicare and Medicaid Innovation], potentially, and it would be a piecemeal effort and certainly much more limited in scope.
Stagnation in Reimbursement Keeps Biomedical Innovation From Reaching All Patients, COA Panel Says
September 9th 2025Panelists at the Community Oncology Alliance Payer Exchange Summit discuss the urgent need for innovative reimbursement models in cancer care to match advancements in biomedical technology and drug discovery.
Read More
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
CNS Metastases in EGFR-Mutant NSCLC: Emerging Therapeutic Strategies and Ongoing Challenges
September 8th 2025Central nervous system (CNS) metastases in EGFR-mutant non–small cell lung cancer (NSCLC) remain a major challenge, with emerging therapies and evolving trial designs aiming to improve outcomes and address unmet needs.
Read More
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
